Repare Therapeutics Inc. (Nasdaq: RPTX) is set to unveil the latest findings from its Phase 1 MYTHIC clinical trial, which investigates the combination of lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers. The presentation, scheduled for December 12, 2024, will feature data from an expansion cohort treated with the recommended Phase 2 dose. These patients harbor specific genetic alterations—CCNE1 amplification or FBXW7 or PPP2R1A mutations—known to drive genomic instability.
The webcast will include insights from Repare’s executive team, along with Brian Slomovitz, M.D., Director of Gynecologic Oncology at Mount Sinai Medical Center. The focus will be on the clinical implications of targeting these mutations with a combination of lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor.
Targeting Genomic Instability in Advanced Cancers
Repare Therapeutics employs a synthetic lethality approach, leveraging its SNIPRx® platform to identify and develop cancer therapies that target genomic instability and DNA damage repair mechanisms. Lunresertib and camonsertib are key components of their pipeline, representing a strategic effort to address unmet needs in precision oncology.
Trial Design and Patient Population
The Phase 1 MYTHIC trial is designed to evaluate the safety, tolerability, and preliminary efficacy of lunresertib in combination with camonsertib. The expansion cohort specifically includes patients with platinum-resistant ovarian and endometrial cancers who have CCNE1 amplification or FBXW7 or PPP2R1A mutations. These genetic alterations are associated with resistance to standard treatments and represent a significant challenge in gynecologic oncology.
Webcast Details
The live webcast will take place on Thursday, December 12, 2024, at 4:30 p.m. Eastern Time. Access details are available on the investor relations section of Repare Therapeutics' website. A replay will be archived for 30 days following the event.
